Overview

KRAS mutations are among the most critical biomarkers in oncology, strongly linked with tumor development, resistance to targeted therapies, and poor prognosis. These mutations occur in approximately 20–50% of colorectal cancers and 15–30% of lung cancers, with changes in codons 12 and 13 of exon 2 being the most clinically significant. Such alterations are known to render standard anti-EGFR therapies ineffective, making rapid and accurate KRAS mutation detection essential for guiding personalized treatment strategies. To address this critical clinical need, Genes2Me offers the KRAS-Q Real-Time PCR Kit - an advanced, in vitro diagnostic solution designed for highly sensitive and specific detection of KRAS somatic mutations in DNA extracted from fresh, frozen, or FFPE tissue samples.

The KRAS-Q Real-Time PCR Kit combines wild-type blocking with allele-specific amplification to accurately detect eight clinically relevant KRAS exon 2 mutations. Detection is based on TaqMan fluorescent probe chemistry (FAM/BHQ2), ensuring high specificity and reliability. An integrated internal control validates DNA quality and assay performance, minimizing the risk of false-negative results.